Drugs · Brain health technique
Erythropoietin (EPO) Analogs
Evidence grade: Experimental
Biologic drugs that stimulate red blood cell production and may have neurotrophic and vascular effects. Includes epoetin alfa (Epogen®, Procrit®) and darbepoetin alfa (Aranesp®), studied experimentally for neuroprotection in stroke, TBI, and neurodegeneration.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Emerging Longevity / Neuroregenerative Agents
- Evidence grade
- Experimental
- Strength of evidence
- Low
How to practice Erythropoietin (EPO) Analogs
Use only under medical supervision or in research settings. Approved clinically for anemia in renal disease or chemotherapy, not for neuroprotection. Typical neuro trials use low-dose IV or subcutaneous regimens (e.g., 40,000 IU weekly). Avoid off-label use due to clotting risk and uncertain long-term safety for brain applications.
The evidence behind Erythropoietin (EPO) Analogs
EPO and its analogs enhance oxygen delivery and have anti-apoptotic and neurotrophic properties. Animal studies show reduced neuronal death after ischemia, and small human studies suggest potential cognitive and mood improvements in TBI and depression. However, higher doses increase thrombotic and hypertensive risks. Mechanism: activation of EPO receptors on neurons and glia improves mitochondrial survival pathways.
More Drugs techniques
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.